RESUMEN
We report the in vitro release profile and comparative pharmacokinetics and biodistribution of a new peroxisome proliferator-activated receptor-γ agonist and cyclooxygenase inhibitor (Lyso-7) free or associated to poly(D,L-lactic acid) nanocapsules (NC) after intravenous administration in mice. Lyso-7 pertains to the class of insulin-sensitizing agents that shows potential beneficial effects in diabetes therapy. Monodispersed Lyso-7 NC with a mean diameter of 273 nm with high encapsulation efficiency (83%) were obtained. Lyso-7 dissolution rate was reduced (2.6-fold) upon loading in NC. The pharmacokinetic parameters were determined using a non-compartmental approach. In comparison with Lyso-7 in solution, the plasma-AUC increased 14-fold, the mean residence time 2.6-fold and the mean half-life (t1/2) 1.5-fold for Lyso-7-NC; the Lyso-7 plasma clearance, distribution volume and elimination rate were reduced 13, 10 and 1.4 fold, respectively, which indicates higher retention of encapsulated Lyso-7 in the blood compartment. Upon association with NC, organ exposure to Lyso-7 was higher in the heart (3.6-fold), lung (2.8-fold), spleen (2.3-fold), kidney (2-fold) and liver (1.8-fold) compared to Lyso-7 in solution. The analysis of whole data clearly indicates that body exposure to Lyso-7 was enhanced and the general toxicity reduced upon nanoencapsulation, allowing further evaluation of Lyso-7 in nonclinical and clinical studies.
Asunto(s)
Inhibidores de la Ciclooxigenasa/administración & dosificación , Inhibidores de la Ciclooxigenasa/farmacocinética , Indoles/administración & dosificación , Indoles/farmacocinética , Nanocápsulas/administración & dosificación , PPAR gamma/agonistas , Tiazolidinedionas/administración & dosificación , Tiazolidinedionas/farmacocinética , Animales , Inhibidores de la Ciclooxigenasa/sangre , Inhibidores de la Ciclooxigenasa/química , Eritrocitos/efectos de los fármacos , Femenino , Hemólisis/efectos de los fármacos , Indoles/sangre , Indoles/química , Riñón/metabolismo , Hígado/metabolismo , Pulmón/metabolismo , Ratones , Miocardio/metabolismo , Nanocápsulas/química , Nanocápsulas/ultraestructura , Tamaño de la Partícula , Bazo/metabolismo , Propiedades de Superficie , Tiazolidinedionas/sangre , Tiazolidinedionas/química , Distribución TisularRESUMEN
INTRODUCTION: The thiazolidinediones (pioglitazone) increases the action of insulin and produces the glycemic control in the patients with type 2 diabetes mellitus. Also, the pharmacological effect may be affected by the purity and pioglitazone plasma concentration. Therefore, the instrumental techniques offer a tool for characterization, identification and/or quantification of the pioglitazone; Raman spectroscopy offers several advantages due to its easy application methodology and structural analysis and the HPLC technique is the gold standard vs. other qualitative and quantitative techniques. OBJECTIVE: The aim of this work is to develop and validate analytical techniques for the characterization of pioglitazone hydrochloride by Raman spectroscopy and quantitative analysis in human plasma by HPLC. MATERIAL AND METHODS: The pioglitazone hydrochloride was analyzed by Raman spectroscopy with a 678 mW power and 3 integration time seconds. The analytical method for quantification by HPLC was validated with the guidelines of the NOM-177SSAl-1998. RESULTS: The Raman technique allowed us to elucidate the functional groups of the pioglitazone hydrochloride and the HPLC technique was linear, accurate, precise, specific and sensitive in the range of 30 to 2000 ng/mL under the chromatographic conditions specified. CONCLUSIONS: The structure analysis by Raman spectroscopy allowed us a complete characterization of the functional groups of pioglitazone hydrochloride effectively and non-destructively. Likewise, the analytical technique for the pioglitazone hydrochloride quantification by HPLC was linear, accurate, precise and sensitive in the range of 30 to 2000 ng/mL under the guidelines.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Hipoglucemiantes/sangre , Espectrometría Raman/métodos , Tiazolidinedionas/sangre , Humanos , Hipoglucemiantes/análisis , Pioglitazona , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Tiazolidinedionas/análisisRESUMEN
This work aimed to investigate plasma pharmacokinetics and tissue distribution of a new acridine derivative 5-acridin-9-ylmethylene-3-(4-methyl-benzyl)-thiazolidine-2,4-dione (AC04) and its 1-oxo-AC04 metabolite disposition in Wistar rats. After a single AC04 1.5 mg/kg intravenous (i.v.) bolus dose, blood samples were taken up to 120 h. Plasma samples were deproteinization, and AC04 and metabolite were quantified by validated liquid chromatography in tandem with mass spectrometry method. Protein binding was determined by ultrafiltration. AC04 tissue disposition was evaluated after i.v. bolus dose. Individual AC04 concentration-time profiles were best fitted by a two-compartment model showing CL(tot) of 3.4 ± 3.4 L/h/kg, Vd(SS) of 137.9 ± 91.4 L/kg, AUC(0-∞) of 788 ± 483 ng·h/mL and a t(1/2) of 45.5 ± 31.5 h. Protein binding was 98.1 ± 1.6%. AC04 showed higher penetration into the lung, spleen and liver, with AUC(0-96) of 798,443, 263,211 and 303,722 ng·h/mL, respectively. The 1-oxo-AC04 metabolite represented 10% of AC04 plasma concentration, showing a t(1/2) of 23.2 ± 10.4 h. These results suggest that, despite the small free plasma fraction, AC04 penetrates extensively reaching high concentrations in most tissues residing for a long time, which is important for its activity on solid tumours. All results combined indicate that AC04 is potentially a good antitumour candidate.